ClinicalTrials.gg
CompletedNCT03422666GLP-2 PlasmaUpdated Jun 14, 2022

Plasma Lipoprotein Response to Glucagon-like Peptide-2

A Phase 2/3 interventional study of Teduglutide and Placebo in Hyperlipidemias, sponsored by University Health Network, Toronto. Completed at 1 site in Canada. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-14.

Sponsored by University Health Network, Toronto · Phase 2/3, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Hyperlipidemias by University Health Network, Toronto — none open to participants now, none under way, none of them phase 3. Hyperlipidemias · University Health Network, Toronto.

Enrollment
8th of 11
10 · median 15
Started
2018
the only one that year
Phase 2/3
6 of 11
none open now
Registered
5th of 11
by date

Among the 11 studies in Hyperlipidemias by University Health Network, Toronto, this one is the 8th largest by enrollment, is the only one that started in 2018, is one of 6 in phase 2/3, and was the 5th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 11 studies in Hyperlipidemias by University Health Network, Toronto is open now. The open studies under Hyperlipidemias, anywhere →

Where they have run

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Hyperlipidemias by University Health Network, Toronto as a file.
02

Study summary

Some of the fat (triglyceride) from the food humans eat gets stored in the bowel. This triglyceride can then be released into the blood when another meal is consumed or in response to hormones. How the gut hormone glucagon-like peptide-2 (GLP-2) releases the triglyceride from the gut is not known. The research team in this study is interested in finding out how teduglutide (a degradation resistant form of GLP-2) releases stored triglyceride from the gut by evaluating how blood lipoproteins respond to teduglutide in healthy individuals.

Read the detailed description

The lipoprotein response will be performed in 15 healthy individuals recruited by newspaper advertisements. Each subject will be their own control, receiving both placebo and teduglutide, administered on separate occasions. A member of the study team will explain the study in detail on visit 1, and if the individual is interested in participating, informed consent will be obtained and preliminary screening will occur on visit 2. On visit 3 \& 4 participants will receive a high fat liquid meal after an overnight fast. Hourly blood samples will be taken for 5 hours, followed by randomized assignment to receive either subcutaneous placebo or teduglutide at visit 3 and the opposite treatment at visit 4. Following the injection, blood samples will be taken every 15 minutes for the first hour and every 30 minutes for the subsequent 3 hours.

03

Conditions studied

  • Hyperlipidemias

Browse trials for

Keywords

  • Intestinal lipoprotein
  • Gut Peptide
  • Chylomicrons
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, aged 18 to 60 years.
  • 20 to 27 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Patients with active inflammatory bowel disease
  • Patients with pre-existing Celiac disease, exocrine pancreatic insufficiency or small bowel malabsorption
  • Patients with active bowel
  • Patients with diabetes mellitus or known/ suspected motility disorders of the gut
  • Patients with decompensated liver disease
  • Patients on ezetimibe or bile acid sequestrants
  • Patients who are pregnant or breastfeeding.
  • Patients with renal disease.
  • Patients on benzodiazepine.
  • Unstable cardiac or respiratory disease
  • Any changes to medication in the preceding month
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Teduglutide

    Teduglutide, up to 0.05mg/kg, subcutaneous, single dose

    Drug: Teduglutide

  • Placebo comparator
    Placebo

    Placebo, subcutaneous, single dose

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Lipoprotein response to teduglutide

    To quantify the plasma lipoprotein response to teduglutide (GLP-2 analogue) injection in healthy individuals

    Time frame: 8 hours

07

Study locations

1 site
  • Toronto General Hopital
    Toronto, Ontario M5G 2C4, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Jun 2021, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2018
First posted
Feb 6, 2018
StartActual
Sep 21, 2018
Primary completionActual
Jun 1, 2021
CompletionActual
Dec 1, 2021
Last update
Jun 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03422666
Responsible party
Sponsor
First posted
Feb 6, 2018
Start date
Sep 21, 2018
Primary completion
Jun 1, 2021
Completion
Dec 1, 2021
Last update
Jun 14, 2022

Study contacts

Gary Lewis, MD
principal investigator · UHN

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion